Robots Atlas>ROBOTS ATLAS
Remedy N1 robotic system — AI-powered endovascular robotic system

Remedy N1

Prototype

Remedy N1 is described by its maker as "the world's first AI-powered endovascular robotic system." It gives physicians tool control and 3D visualization, and through teleoperation it enables procedures to be performed remotely — as the company puts it, "from next door or 5,000 miles away."

The system has two main parts: the robotic system itself, built for complete end-to-end robotic procedures with everything needed for remote intervention in one package, and the software and operator console, providing AI-native visualization and ML-based tool control. Its goal is to extend access to expert endovascular care — the company notes that fewer than 3% of eligible stroke patients worldwide can access endovascular treatment in time.

The N1 System is investigational: its safety and effectiveness for clinical use have not been established, and it is not available for commercial sale. Its milestones include first-in-human studies: in 2024, the first entirely robotic neurointerventional procedures (St. Michael's Hospital, Toronto, led by Dr. Vitor Mendes Pereira), and in 2025, the first entirely remotely controlled neurointerventional procedures. Partner institutions include Mayo Clinic, University of Chicago, Northwell Health, Barrow Neurological Institute, Jackson Memorial (Miami), Monash Health and the UK's NHS. Remedy Robotics raised a $62M Series B led by DCVC to advance the technology.

Key competencies and robot functions

2parameters

Teleoperation

Remote control of a robot by a human operator using interfaces such as joystick, exoskeleton, VR, or programmatic API.

Micromanipulation

The ability to capture, transport, reversibly assemble and release microscopic objects such as cells or bacteria. In the plasmonic nanorobot it is achieved with opto-thermophoretic forces, without a physical gripper.